ICP-723

DRUG3 trials

Sponsors

Beijing InnoCare Pharma Tech Co., Ltd., InnoCare Pharma Inc.

Conditions

Advanced Solid TumorsAdvanced Solid Tumors Harboring NTRK FusionPrimary Central Nervous System Tumors Harboring NTRK FusionSolid Tumors

Phase 1

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

RecruitingNCT04685226

Beijing InnoCare Pharma Tech Co., Ltd.Solid Tumors

Start: 2020-09-27End: 2028-02-25Target: 310Updated: 2025-09-02

Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors

InnoCare Pharma Inc.Advanced Solid Tumors

Start: 2021-07-30End: 2024-07-31Target: 30Updated: 2023-01-20

Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors

RecruitingNCT05745623

Beijing InnoCare Pharma Tech Co., Ltd.Advanced Solid Tumors Harboring NTRK Fusion, Primary Central Nervous System Tumors Harboring NTRK Fusion

Start: 2022-12-27End: 2028-12-25Target: 70Updated: 2025-09-11

Related Papers

Efficacy, safety and pharmacokinetics (PK) of zurletrectinib, a next-generation pan-TRK inhibitor, in pediatric and adolescent patients (pts) with NTRK fusion-positive (NTRK+) solid tumors.

Journal of Clinical Oncology2025-05-28

Updated efficacy and safety of zurlectrectinib in adult patients (pts) with locally advanced or metastatic NTRK fusion–positive (NTRK+) solid tumors.

Journal of Clinical Oncology2025-05-28

Safety, pharmacokinetics (PK), and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor.

Journal of Clinical Oncology2022-06-016 citations